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Introduction:
 
 The MSF-4 (Male Sexual Function 4-item)
questionnaire is a condition-specific four-item scale of
men’s sexuality. We describe two studies that were con-
ducted to assess the reproducibility and validity of the
MSF-4 questionnaire.
 
Methods:
 
 Study 1 was a Phase III, multicenter study with
a double-blind, parallel group design which was con-
ducted in five countries. The objectives were to check the
construct validity and factorial structure of the MSF-4,
along with internal consistency reliability and clinical
validity. Study 2 was a longitudinal, noncomparative,
observational multicenter study to assess the reproduc-
ibility and the clinical and concurrent validity of the
MSF-4.
 
Results:
 
 When exploratory factor analysis was per-
formed with a free number of factors, the variability of
the global MSF-4 score was based on a single factor
across all countries in Study 1 except Spain. There was
a high level of internal consistency reliability (Cron-
bach’s alphas 0.68–0.90) and the MSF-4 was able to
 
significantly discriminate different health states as as-
sessed by the International Prostate Symptom Score
(I-PSS) or Quality of Life (QoL) questionnaire. In study 2,
there was a significant correlation between the MSF-4
and the International Index of Erectile Function (IIEF)
scores (
 
p
 
 
 

 
 .0001 for all items) especially erectile func-
tion (correlation coefficient 
 

 
0.77). The MSF-4 was
able to distinguish among patients with differing de-
grees of benign prostatic hyperplasia (BPH) symptoms
as measured by the I -PSS (
 
p
 
 
 

 
 .0001) and between
those with and without sexual disorders (
 
p
 
 
 

 
 .0001).
 
Conclusion:
 
 The MSF-4 is a psychometrically validated
questionnaire with good reproducibility and clinical va-
lidity, which allows easy and appropriate assessment of
male sexual function in the clinical setting.
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Introduction
 
Benign prostatic hyperplasia (BPH) is a common
phenomenon of the aging process in men [1]. De-
spite the recent increase in awareness of BPH and
the various treatment options available, the rela-
tionship between BPH and sexuality remains under
investigation [2]. However, it is known that both
BPH and some of the treatments for this condition
can have a negative impact on sexual function and
activity [3–6].
In a Swedish study of 435 randomly selected
men aged 50 to 80, the Radiumhemmets question-
naire was used to assess sexual desire, erectile ca-
pacity, orgasm and ejaculation, and the extent to
which declining sexual function caused distress.
Overall, 13% of men in this age group stated that
sex was “very important” to them, 29% stated
that sex was “important,” and 41% stated that it
added “spice to life.” [7] This emphasizes that as-
sessment of sexuality is an important consider-
ation when evaluating treatment outcomes in men
of this age group. Although the frequency of sex-
ual activity naturally declines with age, sexuality
continues to be important for many elderly men
[7,8].
In a further study, 73 French and 44 English
patients with an International Prostate Symptom
Score (I-PSS) superior to 7 were asked to fill out
an 89-item Quality of Life (QoL) questionnaire [8]
to determine which aspects of QoL were most af-
fected by prostatic symptoms and which aspects
were considered to be the most important by pa-
tients. The questionnaire was made of an exhaus-
tive list of QoL concepts measured in specific BPH
questionnaires and concepts chosen from the health-
related QoL classification [9]. Items were derived
from models known as psychometrically sound.
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Such study was conducted in the perspective of de-
veloping a sound QoL questionnaire for BPH. The
major areas considered to be of importance by
these men included sexual activities and satisfac-
tion with sexual relationships. This study con-
firmed the importance of including an assessment
of sexual functioning in evaluating the effect of
BPH, and its treatment, on quality of life.
Various quality-of-life instruments assess inter-
est in sex (sexual desire) and/or sexual function
and questionnaires that are specific to sexual is-
sues are also available [2,10,11]. These include
the Brief Male Sexual Function Inventory (BMSFI)
[12] and the International Index of Erectile Func-
tion (IIEF) [13], which cover the main domains of
male sexual function. However, many question-
naires are too lengthy (most use at least 9 to 20
questions) and have limited reproducibility [10].
The Male Sexual Function-4 item (MSF-4) ques-
tionnaire is a concise survey that is easy to complete
and is available in several languages including French,
English, Spanish, Portuguese, German, Greek, Italian,
Czech, Polish,and Dutch. Each version was obtained
through a linguistic validation process (forward trans-
lations, backward translation). Psychometric proper-
ties were thus checked on the languages involved in
the two studies described hereafter. The MSF-4 is
composed of four items: interest in sex, quality of
erection, achievement of ejaculation, and achievement
of orgasm.
In order to investigate the performance of this
questionnaire, two complementary studies were
carried out. The objective of Study 1 was to ana-
lyze the psychometric properties and clinical valid-
ity of the MSF-4. Study 2 aimed to verify the re-
producibility of the MSF-4 and further assess the
clinical validity of the questionnaire.
 
Patients and Methods
 
Design
 
Study 1 was a 15-week, Phase III, multicenter (71
centers) study with a double-blind, parallel group
design which compared two dosing regimens of
Permixon (320 mg once daily and 160 mg twice
daily). The study was conducted in five countries:
Austria, France, Germany, Portugal, and Spain.
Study 2 was a longitudinal, noncomparative,
observational, multicenter (17 centers) study con-
ducted in France. The primary objective was to
verify the reproducibility (test-retest) of the MSF-4
(Appendix 1) in patients presenting with BPH. The
design called for two administrations of the MSF-4
at a 7-day interval.
 
Patients
 
Inclusion Criteria.
 
In Study 1, men aged 50 to 75
with symptomatic BPH not requiring surgery were
included if they had a diagnosis of BPH for more
than 6 months. An I-PSS score superior to 7 and
less than or equal to 19, a maximum urinary flow
rate (Q
 
max
 
) from 5 to 15 ml/s (for a voided volume
 
 
 
150 and 
 
 
 
400 ml), residual volume less than
150 ml, and a prostatic volume superior to 25 cm
 
3
 
were also required.
Study 2 included men aged over 50 who had
presented with uncomplicated BPH for more than
3 months and engaged in regular sexual activity.
Half of the included patients were to have docu-
mented sexual disorders.
 
Exclusion Criteria.
 
Study 1 excluded patients di-
agnosed as having prostate cancer or prostatitis, or
with a history of bladder, neck, or prostate surgery.
Other criteria for exclusion included those with
complicated BPH (e.g., neurogenic bladder dysfunc-
tion, recurrent urinary tract infection, abnormal
liver function), patients receiving drugs with antian-
drogenic properties during the previous 3 months,
and patients treated within the previous 14 days us-
ing an 
 

 
-adrenoreceptor blocker, finasteride, or any
plant extracts that could have an effect on BPH.
Study 2 excluded patients suffering from com-
plicated BPH, including those with renal impair-
ment, recurrent macroscopic hematuria, acute uri-
nary retention, and urinary infection. Patients with
serious concomitant events taking place in the past
3 months that could have influenced their lives (e.g.,
bereavement, unemployment, serious concomitant
disease) were also excluded.
 
Procedures
 
In Study 1, the MSF-4 was administered at base-
line and at endpoint (15 weeks) or withdrawal.
Additional assessment variables were the I-PSS
and a global question assessing the impact of uri-
nary symptoms on QoL (measured in terms of sat-
isfaction or dissatisfaction).
In Study 2, patients completed the MSF-4 on
two occasions: once at day 0 (baseline) and once at
day 7. The IIEF [13] was completed at baseline.
Medical data collected included the presence or ab-
sence of sexual problems (baseline and endpoint)
and details of any other events that may have influ-
enced sexual function over the course of the study.
 
Statistical Methods
 
In Study 1, the construct validity of the MSF-4
was assessed by exploratory factor analysis (prin-
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cipal component analysis with varimax rotation)
and multitrait analysis, which were performed for
each country and for all five countries together.
Internal consistency reliability was assessed with
Cronbach’s alpha. To establish the clinical validity
of the MSF-4, Spearman correlation coefficients
between the MSF-4 global score and the quantita-
tive clinical variables were calculated as well as
the distribution of the MSF-4 global score accord-
ing to I-PSS items, including the item related to
QoL and the global score. In addition, as the glo-
bal score cannot be assumed to have even approx-
imately the normal distribution form, nonpara-
metric tests were used [14].
In Study 2, the primary objective was to verify
the reproducibility by test-retest of the MSF-4.
This reproducibility was used to assess the stabil-
ity of scores in patients whose state of health was
stable between the two administrations of the
questionnaire. The Wilcoxon signed rank test was
used to compare the evolution of scores between
day 0 and day 7. A linear regression equation of
the global MSF-4 score on day 7 as a function of
the score on day 0 was obtained. The null hypothesis
was that the MSF-4 score at day 7 was a simple
linear function of the score at day 0. Thus, the
nearer the MSF-4 score at day 7 was to the MSF-4
score at day 0, the better was the reproducibility
of the questionnaire.
The calculation of intraclass correlation coeffi-
cient (ICC) values allowed the stability of the
MSF-4 scores to be verified. ICC measurements
are derived from the analysis of variance and are
considered as the ratio of the intersubject variabil-
ity compared to the total variability (a high level
of ICC indicates that the responses of patient re-
mained invariable from one evaluation the other).
The ICC ratio varies from 
 

 
1 to 
 

 
1 and is judged
to be satisfactory from a threshold of 0.80 [15].
Additionally, to analyze the known-group va-
lidity in Study 2, the relationship between the
MSF-4 scores and the presence or absence of sex-
ual disorders and the distribution of I-PSS scores
was investigated.
 
Scoring of the MSF-4
 
Each of the four items is scored on a six-point Lik-
ert scale ranging from 0 to 5. The sex life (global)
score was calculated by the mean of the non-miss-
ing answer given to the four items of the question-
naire (when more than two items out of four had
a missing answer, the score could not be calculated).
Then, the resulting score was linearly transformed
to obtain a score ranging from 0 to 100. The lower
 
the score, the better preserved the sexual function
for both individual items and the index.
 
Results
 
Study 1
 
A total of 810 patients aged 44 to 80 (mean age of
64) were recruited. The mean baseline I-PSS score
was 13.45 (range 7–25). Thirteen patients had an
I-PSS score greater than 19 and six patients had a
score greater than 21. At baseline the QoL ques-
tionnaire showed that 24% of patients were mostly
satisfied to delighted with their condition, 43%
had mixed feelings, and 33% were mostly to terribly
dissatisfied. The mean age and I-PSS score were sim-
ilar across the five countries but there were some
differences in the QoL responses. Whereas 47.62%
of Spanish patients felt mostly satisfied about
spending the rest of their lives with their urinary
condition, only 9.63% of French and 11.54% of
Austrian patients felt the same, with the highest
proportion being mostly dissatisfied to do so (31%
and 34.6%, respectively). In addition, nearly half
of German patients answered “mixed” (equally sat-
isfied and dissatisfied) about spending the rest of
their lives with their urinary condition.
Out of the 810 patients recruited, 721 (89.01%)
completed the MSF-4 at baseline (i.e., 89 patients
did not complete or insufficiently completed the
questionnaire to be taken into account in the anal-
yses) and 692 (85.43%) did so at endpoint. For the
group as a whole, the mean of the transformed glo-
bal sex–life scores at baseline and endpoint for the
five countries were 40.42 and 40.78, respectively.
Significant differences were detected between the
countries at baseline and endpoint (Table 1) [
 
p
 
 
 

 
.0001]. For example, patients in Portugal, Spain,
and Austria had less impaired sexual function than
patients in France and Germany. Thus, at baseline
the mean scores ranged from 27.62 for Spanish pa-
tients to 45.89 for German patients, whereas at
endpoint the respective scores were 26.83 and
45.72. The mean evolution in the MSF-4 score was
0.51, with mean scores ranging from 
 

 
1.22 (Span-
ish patients) to 4.57 (Austrian patients). The differ-
ence in MSF-4 score evolution between the five
countries was significant (
 
p
 
 
 

 
 .0011).
 
Construct Validity.
 
When exploratory factor anal-
ysis was performed on the MSF-4 with a free num-
ber of factors, the variability of the MSF-4 global
score was based on a single factor (factor 1) for all
five countries as a whole. Similar results were ob-
tained when the countries were analyzed individu-
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ally, with the exception of Spain, for which the four
items of the MSF-4 were spread across two factors:
factor 1 was composed of items 2, 3, and 4 whereas
factor 2 was composed of item 1 (Appendix 2).
Overall, the multitrait analysis indicated good
item convergent validity. For all five countries, the
analysis showed that items were correlated to their
scale, with item-scale coefficients ranging from 0.59
(item 1) to 0.87 (item 3). When results from individ-
ual countries were analyzed, the results from Spain
differed from those of the remaining countries. Four
countries (France, Germany, Austria, and Portu-
gal) had equivalent results, with the analysis con-
firming good item-scale correlation (
 
 
 
0.65 for
items 2, 3, 4; 0.46–0.69 for item 1 depending on
the country). Spain had a high item-scale correla-
tion for items 3 and 4 alone.
The internal consistency reliability of the ques-
tionnaire was considered satisfactory for all of the
countries combined and separately and Cronbach’s
alpha ranged from 0.68 to 0.90 depending on the
country. The theoretical Cronbach’s alpha coeffi-
cient for a 10-item scale was also high (
 
 
 
0.84) [16].
 
Clinical Validity.
 
The MSF-4 was able to signifi-
cantly discriminate (
 
p
 
 
 
 
 
.05) between patients ac-
cording to their responses for each of the I-PSS
items at baseline (Fig. 1). The higher the I-PSS
score, the higher the MSF-4 score tended to be.
The MSF-4 also significantly discriminated (
 
p
 

 
.05) between the different QoL responses (Fig. 1).
The trend was that the more dissatisfied a patient
was about spending the rest of his life with his uri-
nary condition, the higher the MSF-4 score.
There was also a trend for older patients to have
a worse (higher) global MSF-4 score than younger
patients. When patients were considered as three
groups, 
 
 
 
60, 60 to 70, and 
 
 
 
70, the difference in
scores between the groups was significant (
 
p
 
 
 
 
 
.05).
 
Study 2
 
Reproducibility.
 
A total of 124 men aged 48 to
87 (mean age 64) were recruited at 17 investigat-
ing centers in France (Table 2). The mean total
I-PSS score for these patients was 12.6 and the
time since diagnosis with BPH ranged from 3 to
287 months (mean 64.3 months). The mean time
between completion of questionnaires was 7.83
days and complete data were available for all but
one patient.
Over the 7-day study period, 103 patients were
considered to be stable (according to their own
judgment and that of the investigator) with respect
to general health, sexual disorders, BPH, and other
events. The mean global MSF-4 score in these pa-
tients on day 0 and day 7 was 41.07 and 43.62, re-
spectively (Table 3). Patients with sexual disorders
had significantly higher MSF-4 scores (
 
p
 
 
 

 
 .0001
for the global score), and the correlation between
the MSF-4 scores and the number of sexual rela-
tions per month was also significant (
 
p
 
 
 

 
 .0001).
 
Table 1
 
The mean global MSF-4 score at baseline and endpoint in Study 1 by country*
 
Mean global MSF-4 score (standard deviation) and internal consistency reliability in Study 1 at baseline, and mean global MSF-4 
score at endpoint
Baseline Endpoint
Country n Mean scores
 
†
 
 (SD) Cronbach alpha n Mean scores
 
†
 
 (SD)
France 184 36.98 (26) 0.90 173 38.38 (27)
Germany 371 45.89 (21) 0.88 361 45.72 (22)
Austria 52 33.75 (21) 0.83 46 37.12 (23)
Portugal 69 33.04 (19) 0.83 67 31.42 (21)
Spain 42 27.62 (15) 0.68 41 26.83 (15)
Five countries together 718 40.42 (23) 0.88 688 40.78 (24)
 
*Score from 0 (no impairment) to 100 (highest impairment).
 
†
 
p 
 

 
 0.0001 for between country comparisons (Kruskal Wallis test).
Figure 1 The mean item and global MSF-4 scores according
to the global QoL item responses of patients in Study 1.
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Linear regression of the MSF-4 score at day 0 as
a function of the score at day 7 gave similar results
(
 
r
 
2
 
 
 

 
 0.84), demonstrating that the reproducibility
of the global score was acceptable. However, there
was a significant evolution of the MSF-4 global
score in the intervening period between the two
evaluations (i.e., between day 0 and day 7) of pa-
tients considered as stable (
 
p
 
 
 

 
 .0071, Wilcoxon
signed rank test). Reproducibility was also evalu-
ated in the stable population by calculation of ICC
values and these ranged from 0.84 to 0.89 for indi-
vidual items (0.92 for the global score): this indi-
cates the good reproducibility of MSF-4, since the
ICC values are above the threshold of 0.80.
 
Clinical Validity.
 
The MSF-4 discriminated be-
tween patients with mild, moderate, and severe
BPH symptoms, as assessed by the I-PSS (Fig. 2).
The results obtained for the global MSF-4 score
were similar to those obtained in Study 1 and the
differences observed for the three severity groups
were significant (
 
p
 
 
 

 
 .0001, Kruskal-Wallis test).
The MSF-4 was also able to discriminate be-
tween patients with sexual disorders and those
without. Patients with sexual disorders had a sig-
nificantly higher MSF-4 global score (
 
p
 
 
 

 
 .0001,
Mann-Whitney-Wilcoxon test) and higher scores
for all individual items, indicating a poor sexual
function (Fig. 3).
The MSF-4 was moderately correlated to pa-
tients’ age and duration of BPH. More interestingly,
the level of correlation with the average monthly
frequency of sexual intercourse was high, indicating
the clinical relevance of the questionnaire (Table 4).
 
Concurrent Validity.
 
The correlation between
the MSF-4 and the IIEF scales was above 0.60
(
 
p
 
 
 

 
 .0001). The highest correlation of the MSF-4
global score was with the erectile function item of
the IIEF (
 

 
0.77) (Table 4).
The MSF-4 global score was significantly related
to age (correlation coefficient of 0.34). This was also
the case for the duration of BPH symptoms, fre-
quency of sexual intercourse, and handicap caused by
sexual disorders (as determined by the investigator).
 
Discussion
 
The MSF-4 was designed as a simple, brief, self-
administered questionnaire on male sexual function.
We reviewed 13 questionnaires used in studies to
evaluate consequences of BPH and/or its treatment
on quality of life and which included a measure of
sexual function. The content of the selected ques-
tionnaires was compared with that of the MSF-4.
This comparison showed that one possible weakness
of the MSF-4 was the lack of detailed assessment of
some of the domains appraised by other instruments
(satisfaction with sexual life, sexual relations, prob-
lems with sexual life, sexual desire). However, the
MSF-4 was designed to be a measure of sexual func-
tion and, as such, the MSF-4 is useful in detecting
sexual difficulties such as ejaculation or erection
problems, which are the domains most commonly
 
Table 2
 
Demographic characteristics of patients in Study 2
 
Characteristics of patients in Study 2 Value (n 
 

 
 124)
Mean age (range) [years] 64.3 (48.0 
 

 
 87.0)
Family status, number (%) of patients:
Lived alone 11 (8.9)
Lived in couple 112 (90.3)
Other 1 (0.8)
Mean total I-PSS score (range) 12.6 (0.0 
 

 
 25.0)
Mean duration of BPH (range) 
[months] 64.3 (3.0 
 

 
 287.0)
Total number (%) of patients treated 
for BPH 88 (71.0)
Medical treatments for BPH, number (%) 
of patients:
Permixon (
 
Serenoa repens
 
) 26 (29.6)
Xatral (alfuzosin) 20 (22.7)
Omix (tamsulosin) 14 (15.9)
Chibro-Proscar (finasteride) 12 (13.6)
Total number (%) of patients with sexual 
disorders 68 (54.8)
Type of sexual disorder, number (%) 
of patients:
Decrease or absence of erection 55 (80.9)
Libido disorder 39 (57.4)
Premature ejaculation 14 (20.6)
Retrograde ejaculation 2 (2.9)
 
BPH, Benign prostatic hyperplasia; I-PSS, International Prostate Symptom Score.
 
Table 3
 
The mean global and item sexual function scores on day 0 and day 7 in Study 2
 
Mean scores (standard deviation) in Study 2 at baseline, changes over time and test-retest reliability (n 
 

 
 103)*
Domain Day 0 Mean change day 7-day 0 (SD) Median change day 7-day 0 p (Sign rank test) ICC
Sexual activity 2.13 (1.2) 0.06 (0.7) 0.00 0.4195 0.84
Erection 2.17 (1.3) 0.00 (0.6) 0.00 0.9925 0.89
Orgasm 2.12 (1.5) 0.19 (0.8) 0.00 0.0092 0.86
Ejaculation 1.80 (1.6) 0.27 (0.8) 0.00 0.0003 0.87
Global (MSF-4) score 41.07 (24.5) 2.56 (10) 0.00 0.0071 0.92
 
*Item scores from 0 to 5 and global score from 0 to 100 ICC; Intra-class correlation coefficient.
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found in other questionnaires. One of the distin-
guishing features of the MSF-4 is that it measures the
quality of erection, in contrast with most other ques-
tionnaires, which assess erections in terms of fre-
quency, erection problems, or difficulty obtaining
and/or maintaining erections. The MSF-4 is also dif-
ferentiated from the other questionnaires reviewed
by the assessment of interest in sex and orgasm
which are evaluated by few questionnaires (Table 5).
The results of the two current studies show that
the MSF-4 is psychometrically and clinically valid
across different cultures, in addition to being
highly reproducible.
In Study 1, the global MSF-4 was supported by
a single factor (factor 1) and showed good item con-
vergent validity in all countries (France, Germany,
Austria, and Portugal) except Spain. The statistical
discrepant results obtained in Spain (two identi-
fied factors) confirmed what was highlighted dur-
ing the linguistic validation process. From a lin-
guistic point of view, items 2, 3, and 4 (factor 1)
refer to sexual functioning rather than to the per-
ception of sexuality as expressed in other lan-
guages. It is difficult to assess sexuality in Spain in
terms of quality without referring to physical con-
siderations; sexuality seems to be assessed in terms
of physical performance by Spanish males.
The internal consistency reliability of the MSF-4
was satisfactory for all countries (considered to-
gether and separately) and it was able to signifi-
cantly differentiate patients based on their I-PSS
and QoL scores. The MSF-4 score was demon-
strated to be I-PSS and age dependent; however,
because the relationship between sexual function
Figure 2 The mean item and global MSF-4 scores of patients
in Study 2 with mild, moderate, and severe BPH symptoms as
assessed by the I-PSS.
Figure 3 The mean item and global MSF-4 scores for pa-
tients with and without sexual disorders in Study 2.
 
Table 4
 
Concurrent and clinical validity of the MSF-4 with 
the IIEF
 
n MSF-4 index
IIEF scales
Erectile function 119
 

 
0.77 (.0001)*
Orgasmic function 122
 

 
0.76 (.0001)
Sexual desire 122
 

 
0.74 (.0001)
Intercourse satisfaction 121
 

 
0.73 (.0001)
Overall satisfaction 120
 

 
0.64 (.0001)
Age 0.34 (.0001)
Duration of BPH 0.22 (.01)
Number of intercourses per month
 

 
0.63 (.0001)
 
Spearman correlation coefficients.
*
 
P
 
 values.
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and BPH symptoms has not been clearly estab-
lished, our findings could be the results of other
factors (poor state of health, for example). How-
ever, in Study 2, the MSF-4 again showed good re-
producibility, and not only was it able to differen-
tiate patients with BPH symptoms of differing
severities (assessed by I-PSS), but it was also able to
differentiate patients based on the presence/absence
of sexual disorders. The presence of a sexual dis-
order was associated with a higher global MSF-4
score, which in turn was significantly correlated
with a lower frequency of sexual intercourse.
Responses to the sexual function instrument dif-
fered for certain countries. The Spanish sample had
scores lower (higher sexual functioning) than in the
other countries. Again, as previously mentioned, lin-
guistic issues should be taken into account when in-
terpreting such results. Given that in Spain physi-
cal performance seems to be important, response
choices might not be as relevant as in other coun-
tries. Checking the relevance of more specific quan-
tifier response choices for items 2, 3, and 4 could be
the subject of further research. However, previous
cross-cultural studies [8] showed cultural differ-
ences in the report of sexual problems or sexual ac-
tivities [17]. Moreover, the fact that the Spanish
sample had the lowest number of patients in study
1 (42 vs. 371 in Germany and 184 in France)
should also be taken into account when interpret-
ing the results. We recommend checking the struc-
ture of the MSF-4 again in a larger Spanish sample.
Nevertheless, the MSF-4 was extremely well ac-
cepted with very few missing data: 85 percent (study
1) and 99 percent (study 2) of the questionnaires
were fully completed. The MSF-4 showed good test-
 
retest reproducibility, although there was a signifi-
cant evolution in the global score between day 0 and
day 7 in study 2 (
 
p
 
 
 
 .0071). The study protocol did
not call for a visit on day 7, and because the clinical
stability of patients was assessed through a telephone
interview—both by the investigator and the pa-
tient—no medical examination could be made at
that time. However, several questions were asked
and answers crossed in order to ensure stability over
7 days. Moreover, the inclusion criteria called for
stability in treatment over 7 days and such a criterion
was met. The change in the median scores between
day 0 and day 7 was null for all items (Table 3). This
kind of variation has been previously reported with
other questionnaires in other settings [18].
Concurrent validity analysis showed a significant
correlation between the MSF-4 and the IIEF, which
could call into question the use of the MSF-4 ver-
sus the IIEF. Such is the interest of the MSF-4,
which is highly correlated with a psychometrically
sound instrument and is shorter. Hence, in daily
practice the instrument can be useful for clini-
cians; it will require just a few minutes to com-
plete and will therefore not burden patients. Also,
having only four items makes the score calculation
quick and easy and enables clinicians to make a
quick estimate of a patient’s sexual status. Being
short, the MSF-4 could also be included in a battery
of questionnaires—with a generic instrument, for ex-
ample—without increasing the time for completion.
In conclusion, the MSF-4 is a psychometrically
validated questionnaire with good reproducibil-
ity and clinical validity, allowing easy and appro-
priate assessment of male sexual function in BPH
clinical settings.
Table 5 Review of 13 questionnaires and comparison with the MSF-4
Satisfaction 
with 
sexual life
Sexual activity/
sexual relations Erection
Problems 
with
sexual life
Sexual desire/
arousal
Interest in sex/
importance of sex Ejaculation
Pleasure/
orgasm
QoL of patients with BPH
[19] ✓
Veterans Affairs [20] ✓ ✓
BPH patient questionnaire 
[21]
✓ ✓
MOS Sexual Module [22] ✓ ✓ ✓
Urolife [23] ✓ ✓
QOL-BPHY [24] ✓ ✓ ✓
SFI [12] ✓ ✓ ✓ ✓ ✓
QOL-BPH [25] ✓ ✓ ✓ ✓
DAN-PSS1 [26] ✓ ✓
SFQ [27] ✓ ✓ ✓
SFQ [28] ✓
Specific questions on sexual
function [8] ✓ ✓ ✓ ✓ ✓ ✓
IIEF [13] ✓ ✓ ✓ ✓
MSF-4 ✓ ✓ ✓ ✓
342 Marquis and Marrel
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Appendix 1 MSF-4 (Male Sexual Function-4 item) questionnaire
How would you rate the following aspects of your life?
Circle one answer for each question :
Very strong Strong Moderate Weak Very weak None
1. Your interest in sex 0 1 2 3 4 5
2. The quality of your erection 0 1 2 3 4 5
3. Achieving orgasm 0 1 2 3 4 5
4. Achieving ejaculation 0 1 2 3 4 5
Appendix 2 Exploratory factor analysis of the MSF-4 across countries*
All countries France Germany Austria Portugal Spain
MSF-4 items Factor 1 Factor 1 Factor 1 Factor 1 Factor 1 Factor 1 Factor 2
1. Interest in sex 0.75 0.82 0.73 0.66 0.67 0.17 0.91
2. Quality of erection 0.84 0.85 0.85 0.87 0.81 0.72 0.49
3. Orgasm 0.93 0.94 0.93 0.90 0.89 0.87 0.18
4. Ejaculation 0.91 0.92 0.92 0.82 0.88 0.88 0.22
*Item-factor correlations.
